Cell cycle progression score and treatment decisions in prostate cancer: Results from an ongoing registry

Current Medical Research and Opinion

Volumn 30, Issue 6, 2014, Pages 1025-1031

  Crawford, E David ^a   Scholz, Mark C ^b   Kar, Ashok J ^c   Fegan, Jeffrey E ^d   Haregewoin, Abebe ^e   Kaldate, Rajesh R ^e   Brawer, Michael K ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b Prostate Oncology Specialists   (United States)

^c ST JOSEPH HOSPITAL   (United States)

^d Rocky Mountain Urology Assoc   (United States)

^e Myriad Genetic Laboratories   (United States)

Author keywords

Biomarker; CCP score; Clinical utility; Physician surveys; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CELL CYCLE PROGRESSION; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL DECISION MAKING; MEDICAL INFORMATION; PHYSICIAN; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SCORING SYSTEM; CELL CYCLE; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; REGISTER; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CELL CYCLE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; REGISTRIES; RISK ASSESSMENT;

EID: 84900809745     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.899208     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
2. SEER Program (National Cancer Institute [US]), National Center for Health Statistics (US), National Cancer Institute (US). Surveillance Program. National Cancer Institute (US) Cancer Statistics Branch, National Cancer Institute (US). Cancer Control Research Program. SEER Stat Fact Sheets: Prostate. Cancer Stat Fact Sheets. Bethesda, MD: US Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 2012
3. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med 2007;357:2696-705
4. Martin RM. Commentary: prostate cancer is omnipresent, but should we screen for it? Int J Epidemiol 2007;36:278-81
5. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004;22:2141-9
6. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203-13
7. Andriole GL, Crawford ED, Grubb 3rd RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360: 1310-19
8. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-71
9. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol 2013;190:419-26
10. Cooperberg MR, Freedland SJ, Pasta DJ, et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 2006;107:2384-91
11. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 1995;154:2144-8
12. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12:245-55
13. Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013;31:1428-34
14. Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012;106:1095-9
15. Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013;86:848-53
16. Bishoff JT, Freedland SJ, Gerber L, et al. Prognostic utility of the CCP score generated from biopsy in men treated with prostatectomy. J Urol 2014; epub ahead of print. doi:10.1016/j.juro.2014.02.003
17. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106-31
18. Pothier K, Gustavsen G. Combating complexity: partnerships in personalized medicine. Personalized Medicine 2013;10:387-96
19. Malone B. Molecular diagnostics reimbursement in flux. Clinical Laboratory News 2013;39(1). Available at: http://www.aacc.org/publications/cln/ 2013/january/Pages/Molecular.aspx#
20. Penson DF, Chan JM. Prostate cancer. J Urol 2007;177:2020-9
21. American Cancer Society. Prostate Cancer. Available at: http://www.can-cer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key- statistics [Last accessed 16 December 2013]
22. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83
23. Staub LP, Lord SJ, Simes RJ, et al. Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation. BMC Med Res Methodol 2012;12:12
24. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991;11:88-94
25. Hillner BE, Tosteson TD, Tosteson AN, et al. Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry. Med Care 2013;51:361-7